Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CAPR 
Capricor Therapeutics Inc (CAPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: CAPR (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 177.49% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 525.83M USD | Price to earnings Ratio - | 1Y Target Price 43.71 |
Price to earnings Ratio - | 1Y Target Price 43.71 | ||
Volume (30-day avg) 1504489 | Beta 4.11 | 52 Weeks Range 3.52 - 23.40 | Updated Date 04/1/2025 |
52 Weeks Range 3.52 - 23.40 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -181.71% | Operating Margin (TTM) -69.16% |
Management Effectiveness
Return on Assets (TTM) -23.21% | Return on Equity (TTM) -48.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 375211560 | Price to Sales(TTM) 23.61 |
Enterprise Value 375211560 | Price to Sales(TTM) 23.61 | ||
Enterprise Value to Revenue 16.85 | Enterprise Value to EBITDA -2.73 | Shares Outstanding 45676200 | Shares Floating 40145727 |
Shares Outstanding 45676200 | Shares Floating 40145727 | ||
Percent Insiders 16.76 | Percent Institutions 38.09 |
Analyst Ratings
Rating 4.57 | Target Price 41.29 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Capricor Therapeutics Inc
Company Overview
History and Background
Capricor Therapeutics Inc. was founded in 2005. It is a biotechnology company focused on developing and commercializing cell and exosome-based therapeutics for severe diseases. Key milestones include clinical trial progress for its lead candidate, CAP-1002, and partnerships for development and commercialization.
Core Business Areas
- Cell Therapy Development: Focuses on the development of allogeneic cell therapies, particularly CAP-1002 for Duchenne Muscular Dystrophy (DMD) and other indications.
- Exosome Technology: Developing engineered exosomes for targeted delivery of therapeutic payloads.
Leadership and Structure
Linda Marbu00e1n, Ph.D., is the Chief Executive Officer. The company has a board of directors and a management team overseeing research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- CAP-1002: An allogeneic cardiac-derived cell therapy being developed for the treatment of Duchenne Muscular Dystrophy (DMD) and potentially other cardiac conditions. Currently seeking FDA approval. Market share is not yet established, as it is not yet approved. Competitors in the DMD space include Sarepta Therapeutics (SRPT), PTC Therapeutics (PTCT), and Solid Biosciences (SLDB), which are developing gene therapies and other treatments for DMD.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with significant investment in cell and gene therapies. Regulatory pathways are complex and require extensive clinical data for approval.
Positioning
Capricor Therapeutics is positioned as a developer of cell-based therapies for unmet medical needs, particularly in DMD. Its competitive advantages include its proprietary cell therapy platform and clinical trial data.
Total Addressable Market (TAM)
The TAM for DMD therapies is estimated to be in the billions of dollars. Capricor is positioned to capture a share of this market with successful commercialization of CAP-1002.
Upturn SWOT Analysis
Strengths
- Proprietary cell therapy platform
- Positive clinical trial data for CAP-1002
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on a single lead product candidate
- Uncertainty regarding regulatory approval
Opportunities
- Potential approval and commercialization of CAP-1002
- Expansion of cell therapy platform to other indications
- Strategic partnerships with larger pharmaceutical companies
- Advancements in exosome technology
Threats
- Competition from other DMD therapies
- Regulatory hurdles and delays
- Clinical trial failures
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- SRPT
- PTCT
- SLDB
Competitive Landscape
Capricor is a smaller player compared to Sarepta and PTC Therapeutics. Its advantages lie in its cell therapy approach, but it faces challenges in terms of resources and market access.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Cannot provide historical growth trends without data.
Future Projections: Future projections depend on regulatory approval and commercialization success of CAP-1002. Analyst estimates are unavailable.
Recent Initiatives: Recent initiatives include advancing CAP-1002 through clinical trials and seeking regulatory approval, also expanding exosome development.
Summary
Capricor Therapeutics is a biotechnology company with a promising cell therapy platform, but faces challenges due to limited resources and regulatory uncertainty. Positive clinical trial data for CAP-1002 is a key strength, while reliance on a single lead product and competition from larger companies pose risks. Successful commercialization and expansion into other indications are critical for future growth.
Similar Companies
- SRPT
- PTCT
- CRIS
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on available information and is subject to change. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Capricor Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2007-02-13 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 160 | Website https://www.capricor.com |
Full time employees 160 | Website https://www.capricor.com | ||
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.